COVID-19 pandemic slowed progress toward ending HIV epidemic in the U.S.

The COVID-19 pandemic slowed previous gains made in controlling HIV blood levels and worsened health disparities, according to UC Francisco researchers leading the largest U.S. evaluation of the impact of the public health crisis on people with HIV.

Boehringer seeks approval for lung fibrosis drug following Phase III win

Boehringer’s nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B). Image credit: Tada Images / Shutterstock. Boehringer Ingelheim is seeking regulatory approval for nerandomilast after

September 16, 2024

First clinical test of RNA editing restores missing protein in genetic disease, Wave says

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 17, 2024

Short, daily reflection sessions help health care workers combat burnout

Watching short, web-based tutorials that inspire health care workers to contemplate awe, gratitude and kindness can promote enduring improvements in mental health outcomes such as

December 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.